Open-source software has transformed how life sciences organizations approach analytics. Tools such as R offer flexibility, rapid innovation, and a rich diversity of community-developed packages. However, open-source adoption in regulated clinical environments comes with real challenges. Success depends not on whether open source is utilized, but on how it is implemented, governed, and maintained. Key challenges and solutions are addressed in the latest white paper by d-wise, Implementing R in Modern Life Sciences, and outlined briefly here. By understanding the major obstacles to implementing R and the best practices to overcome them, life science organizations can unlock the full potential of open source while maintaining confidence in their results.
The Promise of Open Source in Clinical Analytics
Open-source tools undergo a rapid evolution. New statistical techniques, visualization approaches, and analytical frameworks appear in open-source packages far sooner than in commercially available software. For clinical teams, this means faster access to modern methods, greater flexibility in analysis design, and easier integration with other technologies1. However, adoption of R without stringent management can quickly become a risk to clinical analytics and compliance.
Core Challenges of Open Source in Clinical Use
As described in Implementing R in Modern Life Sciences, the utilization of open-source software can present several challenges that need to be thoughtfully considered and addressed before adoption2,3. These include:
- Rapid evolution: Packages and language versions change frequently, which allows innovation but can break existing workflows and create inconsistencies across users.
- Variable quality: Open-source packages are developed by contributors with different coding standards and testing practices. Even widely used packages may contain errors.
- Reproducibility issues: Different package versions or missing dependencies can lead to different outcomes or failure to run code altogether.
- Governance gaps: Without clear policies, teams may not know which packages are approved, who can install software, or how updates are introduced.
- Regulatory concerns: Clinical deliverables require defensible processes, documentation, and traceability, but these areas are not automatically addressed by open-source tools.
These challenges do not present a barrier to the use of open source in clinical, regulated environments, but emphasize the importance of implementing R in a managed way that ensures reproducibility and compliance while supporting innovation and high-quality outcomes.
Best Practices for Use of Open-Source Solutions in the Life Sciences
As organizations adopt open-source solutions across research, analytics, data management, and manufacturing, it is essential to use them in a way that ensures reliability, security, and regulatory compliance. There are several best practices to help life sciences teams successfully evaluate, implement, and manage open-source solutions while maintaining quality, data integrity, and long-term sustainability.
Best Practice #1: Separate Innovation from Regulation
A foundational best practice for implementing R is to maintain two distinct environments. An exploratory environment for experimentation and method development, and a validated environment for producing clinical deliverables4,5. This separation allows analysts to explore new approaches freely without introducing risk into regulated workflows. Only well-understood, risk-assessed tools are promoted into the validated environment.
Best Practice #2: Apply Risk-Based Validation
Attempting to fully validate every open-source component is impractical. Instead, organizations should define acceptable risk levels by use case, assign risk profiles to packages, and validate only what is necessary for specific purposes6. Higher-risk packages receive deeper testing. Lower-risk packages may require lighter controls. This approach helps to align effort with impact.
Best Practice #3: Control Package Selection
Installing only what is required reduces validation burden, limits licensing and compliance complexity, minimizes dependency conflicts, and reduces maintenance effort. Each package should have a documented purpose tied to specific analytical needs6,7.
Best Practice #4: Manage Updates Deliberately
Updates can present a major source of instability. Version drift can introduce issues in reproducibility and analytical outcomes. However, organizations can implement strategies to minimize the impact and risk of updates by monitoring new releases, scheduling updates at defined intervals, testing changes before deployment, and keeping exploratory and validated environments separate6. This protects validated workflows and reduces the occurrence of incompatibility issues.
The Solution: SCE and Managed R Environments
Organizations looking to implement best practices for open-source software can look for Statistical Computing Environments (SCEs) integrated with R management. These SCEs can embed best practices into the platform itself. An SCE is a centralized, secure, and validated digital workspace that can import, manage, analyze, and report on data. In clinical settings, these environments must be built for a purpose to ensure efficiency, accuracy, and compliance in the face of complex analyses.
At d-wise, custom SCE services allow effective management of R environments that are both scalable and supported by risk-based validation. Tailored to support any team at any stage of the clinical process, d-wise’s custom SCEs ensure that the value of data is maximized with R while supporting efficient and compliant open source workflows.
Conclusion: Excel Any Stage of the Development Process with R
Open-source analytics offers unparalleled innovation for clinical teams across the clinical development process, but realizing its full potential requires disciplined management to ensure challenges are addressed appropriately and best practices are implemented effectively. The white paper, Implementing R in Modern Life Sciences, explores these challenges and best practices in depth, offering practical guidance for building compliant, scalable, and innovative R environments, including the implementation of the d-wise custom SCE.
Download Implementing R in Modern Life Sciences to learn how a risk-based, managed approach to open source, along with d-wise’s custom SCE solutions, can transform your clinical analytics strategy.
Don’t forget to follow us on LinkedIn to stay up to date on all industry and company news.
References
1. Giorgi FM, Ceraolo C, Mercatelli D. The R Language: An Engine for Bioinformatics and Data Science. Life. 2022;12(5):648. doi:10.3390/life12050648
2. Chan C hong, Schoch D. rang: Reconstructing reproducible R computational environments. PLOS ONE. 2023;18(6):e0286761. doi:10.1371/journal.pone.0286761
3. Prajapati K, Kumar P. Exploring Use of R for Clinical Trials. In: Strategic Implementation. PharmaSUG; 2018.
4. Kenneth G. SAS vs R (Open Source) for Pharma and Life Sciences. Appsilon. December 2023. Accessed February 3, 2026. https://www.appsilon.com/post/r-vs-sas-pharma-life-sciences
5. Schwartz M, Harrell FJr, Rossini A, Francis I. R: Regulatory Compliance and Validation Issues – A Guidance Document for the Use of R in Regulated Clinical Trial Environments. The R Foundation for Statistical Computing; 2021. Accessed February 3, 2026. https://www.r-project.org/doc/R-FDA.pdf
6. Forward Digital. Open Source Software Best Practices and Supply Chain Risk Management. Forward Digital; 2024:1-58. Accessed February 3, 2026. https://assets.publishing.service.gov.uk/media/661ff8b83771f5b3ee757fc5/Open_Source_Software_Best_Practices_and_Supply_Chain_Risk_Management.pdf
7. Wendt CJ, Anderson GB. Ten simple rules for finding and selecting R packages. PLoS Comput Biol. 2022;18(3):e1009884. doi:10.1371/journal.pcbi.1009884
